In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Church & Dwight

This article was originally published in The Rose Sheet

Executive Summary

Firm will pay approximately $254 mil. to purchase Kelso & Co.'s 50% interest in Armkel, with sale expected to close around May 30, Princeton, N.J. company announces May 6. Purchase is expected to have a negative impact on C&D's second and third quarter earnings, but likely will be accretive by early 2005, firm says. C&D acquired Armkel in a 50/50 joint venture with Kelso in 2001 (1"The Rose Sheet" May 14, 2001, p. 9). Firm predicts Q1 diluted net income per share will increase 40% to $.70 per share and revenue will rise 19% to $296 mil., boosted by a longer quarter and the recent acquisition of Unilever's North American oral care business. First quarter results will be announced May 11...

You may also be interested in...



Church & Dwight U.S. Personal Care Sales Near $500 Mil. With C-W Brands

Church & Dwight's U.S. personal care product sales will increase more than three-fold to nearly $500 mil. with the acquisition of the Carter-Wallace consumer brands. Revenues for Church & Dwight's personal products business currently total about $150 mil., according to the company.

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.

Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel

Cerevel, which AbbVie is spending $8.7bn to acquire, unveiled topline results from the TEMPO-3 study of tavapadon, which an analyst said represents potentially a $1bn opportunity.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012109

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel